NCT07449052Not yet recruiting
Comprehensive Invasive Physiological Evaluation of Obstructive Coronary Artery Disease
Inclusive Invasive Physiological Assessment in Angina Syndromes - Obstructive Coronary Artery Disease
Source: ClinicalTrials.gov · Last updated 1 May 2026
Brief summary (registry, in English)
The goal of this clinical trial is to test whether adding coronary function testing and starting targeted medical treatment for identified vasomotor disorders will also improve angina symptoms and quality of life in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention. The main question it aims to answer is: Does performing coronary function testing in patients with obstructive coronary artery disease who undergo percutaneous coronary intervention lead to better relieve of angina symptoms and improvement in quality of life? Researchers will compare this group undergoing coronary function testing with a control group who will solely undergo percutaneous coronary intervention. Participants will: * Undergo percutaneous coronary intervention and coronary function testing in the intervention arm * Undergo percutaneous coronary intervention in the control arm
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 450 (estimated)
- First submitted
- 22 Jan 2026
- Start date
- 1 May 2026
- Primary completion date
- 1 Oct 2028
- Lead sponsor
- UMC Utrecht
- Diseases
- Coronary artery disease
- NCT number
- NCT07449052
What you commit to
- Study type: Interventional
- Planned participants: 450
- From 1 May 2026 to the primary completion date, 1 Oct 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior coronary artery bypass graft surgery.
Other illness
- Severe valvular disease
- Renal impairment (estimated glomerular filtration rate \<30mL/min)
Lab values
- Known severe left ventricular dysfunction (left ventricular ejection fraction by any imaging modality)
Other
- Stenosis \>90% in the target vessel or a stenosis deemed unsafe for pressure wire instrumentation
- Contra-indications for the use of adenosine or acetylcholine
- Expected inability to conform to the clinical follow-up
- Unable or unwilling to use the ORBITA-app
- Life expectancy of less than 12 months.
Who the study is looking for
- Patients \>18 years of age
- Hemodynamically relevant obstructive coronary artery disease (as assessed by pressure wire evaluation) in the left anterior descending coronary artery amenable to percutaneous coronary intervention at the discretion of the operator.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.